ProKidney Corp. (PROK)
NASDAQ: PROK
· Real-Time Price · USD
0.86
-0.03 (-2.89%)
At close: May 01, 2025, 3:59 PM
0.82
-4.67%
After-hours: May 01, 2025, 04:03 PM EDT
-2.89% (1D)
| Bid | 0.82 |
| Market Cap | 251.78M |
| Revenue (ttm) | 76K |
| Net Income (ttm) | -102.15M |
| EPS (ttm) | -0.62 |
| PE Ratio (ttm) | -1.39 |
| Forward PE | -1.48 |
| Analyst | Hold |
| Ask | 1 |
| Volume | 417,457 |
| Avg. Volume (20D) | 776,162 |
| Open | 0.91 |
| Previous Close | 0.89 |
| Day's Range | 0.85 - 0.95 |
| 52-Week Range | 0.46 - 4.44 |
| Beta | 1.59 |
About PROK
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was fo...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 30, 2021
Employees 204
Stock Exchange NASDAQ
Ticker Symbol PROK
Website https://www.prokidney.com
Analyst Forecast
According to 4 analyst ratings, the average rating for PROK stock is "Hold." The 12-month stock price forecast is $6, which is an increase of 597.51% from the latest price.
Stock Forecasts10 months ago
-5.33%
ProKidney shares are trading lower after the compa...
Unlock content with
Pro Subscription
